Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.
Shi W, et al. Among authors: wardley a.
Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805.
Ann Oncol. 2018.
PMID: 29701764
Free PMC article.
No abstract available.